ArborGen Holdings (ARB) H2 2024 earnings summary

Executive summary

• Achieved record revenue of $67.7m, up 21% year-over-year, and record Adjusted US GAAP EBITDA of $12.8m, up 39% from prior year.

• Brazil contributed 39% of seedling sales revenue, up from 30% last year, with record sales, pricing, and margins.

• US South saw a 5% revenue increase despite a 5% drop in sales volumes, driven by higher value advanced genetics seedlings.

• Leadership transition with new CEO Justin Birch and key management appointments.

• Strategic focus remains on US South and Brazil, with divestment of non-core assets and cost optimization.

Financial highlights

• Revenue: $67.7m (+21% YoY); Gross profit: $24.0m (+32% YoY).

• Adjusted US GAAP EBITDA: $12.8m (+39% YoY); US GAAP EBITDA: $7.6m (-26% YoY, due to one-off costs).

• Net loss after tax improved to $0.2m from $2.5m loss prior year.

• Net debt at $14.4m as of 31 March 2024; cash and equivalents at $5.6m.

• One-off costs totaled $5.2m, including CEO transition, seed provision, and VAT allowance.

Outlook and guidance

• Expect continued growth momentum in Brazil and flat sales volumes in the US for FY25.

• Focus on transitioning customers to higher value products and expanding production capacity, especially in Brazil.

• Increased investment in team and nurseries, offset by cost savings from asset sales and closures.